Association between residual islet beta‐cell function and achieving the target of time in range in inpatients with type 2 diabetes undergoing antidiabetic treatment: An observation study

Abstract

AbstractAimTo assess whether the beta‐cell function of inpatients undergoing antidiabetic treatment influences achieving time in range (TIR) and time above range (TAR) targets.Materials and MethodsThis cross‐sectional study included 180 inpatients with type 2 diabetes. TIR and TAR were assessed by a continuous glucose monitoring system, with target achievement defined as TIR more than 70% and TAR less than 25%. Beta‐cell function was assessed by the insulin secretion‐sensitivity index‐2 (ISSI2).ResultsFollowing antidiabetic treatment, logistic regression analysis showed that lower ISSI2 was associated with a decreased number of inpatients achieving TIR (OR = 3.10, 95% CI: 1.19‐8.06) and TAR (OR = 3.40, 95% CI: 1.35‐8.55) targets after adjusting for potential confounders. Similar associations still existed in those participants treated with insulin secretagogues (TIR: OR = 2.91, 95% CI: 0.90‐9.36, P = .07; TAR, OR = 3.14, 95% CI: 1.01‐9.80) or adequate insulin therapy (TIR: OR = 2.84, 95% CI: 0.91‐8.81, P = .07; TAR, OR = 3.24, 95% CI: 1.08‐9.67). Furthermore, receiver operating characteristic curves showed that the diagnostic value of the ISSI2 for achieving TIR and TAR targets was 0.73 (95% CI: 0.66‐0.80) and 0.71 (95% CI: 0.63‐0.79), respectively.ConclusionsBeta‐cell function was associated with achieving TIR and TAR targets. Stimulating insulin secretion or exogenous insulin treatment could not overcome the disadvantage of lower beta‐cell function on glycaemic control.